Publicaciones en colaboración con investigadores/as de Hospital Clinic Barcelona (23)

2022

  1. Advances in Urologic Oncology “OncoUrology Forum Special Edition”: The best of 2020

    Actas Urologicas Espanolas, Vol. 46, Núm. 4, pp. 214-222

  2. Efficacy of enzalutamide in subgroups of men with metastatic hormone-sensitive prostate cancer based on prior therapy, disease volume, and risk

    Prostate Cancer and Prostatic Diseases, Vol. 25, Núm. 2, pp. 274-282

  3. Improved Survival with Enzalutamide in Patients with Metastatic Hormone-Sensitive Prostate Cancer

    Journal of Clinical Oncology, Vol. 37

  4. The impact of enzalutamide on quality of life in men with metastatic hormone-sensitive prostate cancer based on prior therapy, risk, and symptom subgroups

    Prostate, Vol. 82, Núm. 13, pp. 1237-1247

2021

  1. Efficacy of Enzalutamide plus Androgen Deprivation Therapy in Metastatic Hormone-Sensitive Prostate Cancer by Pattern of Metastatic Spread: ARCHES Post Hoc Analyses

    The Journal of urology, Vol. 205, Núm. 5, pp. 1361-1371

  2. Reply by Authors

    The Journal of urology, Vol. 205, Núm. 5, pp. 1371

2020

  1. Advances in urologic oncology “OncoForum”: The best of 2019

    Actas Urologicas Espanolas, Vol. 44, Núm. 9, pp. 586-596

  2. Androgen deprivation therapy in patients with localized disease: Comparison with curative intent treatments and time to castration resistance. Results of the Spanish Prostate Cancer Registry

    Actas Urologicas Espanolas, Vol. 44, Núm. 3, pp. 156-163

  3. Efficacité de l’enzalutamide (ENZA) + traitement par suppression androgénique (TSA) dans le cancer de la prostate hormonosensible métastatique (mHSPC) en fonction de la localisation des métastases : analyses post-hoc de l’étude ARCHES

    Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie, Vol. 30, Núm. 13, pp. 745

2018

  1. Developments in urologic oncology “OncoForum”: The best of 2017

    Actas Urologicas Espanolas

2017

  1. Consenso sobre el manejo del cáncer de próstata resistente a la castración avanzado en España

    Archivos Espanoles de Urologia, Vol. 70, Núm. 9, pp. 777-791

  2. Developments in urologic oncology «OncoForum»: The best of 2016

    Actas Urologicas Espanolas

  3. Diagnosis and treatment for clinically localized prostate cancer. Adherence to the European Association of Urology clinical guidelines in a nationwide population-based study – GESCAP group

    Actas Urologicas Espanolas, Vol. 41, Núm. 6, pp. 359-367

  4. Padeliporfin vascular-targeted photodynamic therapy versus active surveillance in men with low-risk prostate cancer (CLIN1001 PCM301): an open-label, phase 3, randomised controlled trial

    The Lancet Oncology, Vol. 18, Núm. 2, pp. 181-191

2016

  1. Avances en uro-oncología «OncoForum»: lo mejor de 2015

    Actas Urologicas Espanolas

  2. Expert opinion on first-line therapy in the treatment of castration-resistant prostate cancer

    Critical Reviews in Oncology/Hematology, Vol. 100, pp. 127-136

  3. Tendencias de tratamiento en el cáncer de próstata clínicamente localizado. Análisis poblacional a nivel nacional: grupo GESCAP

    Actas Urologicas Espanolas, Vol. 40, Núm. 4, pp. 209-216

2015

  1. Avances en uro-oncología «oncoForum»: lo mejor de 2014

    Actas Urologicas Espanolas, Vol. 39, Núm. 5, pp. 271-278

  2. The metabolic syndrome and its components in patients with prostate cancer on androgen deprivation therapy

    Journal of Urology, Vol. 193, Núm. 6, pp. 1963-1969

2014

  1. Avances en uro-oncología «oncoForum»: lo mejor de 2013

    Actas Urologicas Espanolas, Vol. 38, Núm. 8, pp. 491-498